Braidwell LP Buys New Holdings in Avalo Therapeutics, Inc. $AVTX

Braidwell LP purchased a new position in shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 1,629,182 shares of the company’s stock, valued at approximately $30,107,000. Braidwell LP owned 3.04% of Avalo Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Boothbay Fund Management LLC bought a new stake in Avalo Therapeutics in the second quarter valued at approximately $56,000. Dimensional Fund Advisors LP bought a new position in shares of Avalo Therapeutics during the 3rd quarter worth approximately $143,000. AlphaCentric Advisors LLC acquired a new position in shares of Avalo Therapeutics during the 1st quarter worth approximately $174,000. Jump Financial LLC acquired a new position in shares of Avalo Therapeutics during the 4th quarter worth approximately $238,000. Finally, Persistent Asset Partners Ltd bought a new stake in Avalo Therapeutics in the 4th quarter valued at $274,000. Institutional investors and hedge funds own 87.06% of the company’s stock.

Insider Buying and Selling

In related news, insider Mittie Doyle sold 1,450 shares of the firm’s stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $18.00, for a total transaction of $26,100.00. Following the transaction, the insider directly owned 51,776 shares of the company’s stock, valued at approximately $931,968. This trade represents a 2.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 3,129 shares of company stock worth $59,680 over the last 90 days. 4.46% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms have commented on AVTX. Guggenheim set a $48.00 price objective on shares of Avalo Therapeutics and gave the stock a “buy” rating in a research report on Friday, August 7th. HC Wainwright dropped their price objective on shares of Avalo Therapeutics from $35.00 to $30.00 and set a “buy” rating on the stock in a research report on Friday, August 7th. BTIG Research restated a “buy” rating and set a $58.00 target price on shares of Avalo Therapeutics in a research note on Tuesday, June 16th. Bank of America initiated coverage on shares of Avalo Therapeutics in a report on Friday, June 12th. They set a “buy” rating and a $35.00 target price for the company. Finally, Wall Street Zen upgraded shares of Avalo Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, August 16th. Thirteen analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Avalo Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $45.10.

Avalo Therapeutics Price Performance

AVTX opened at $19.34 on Thursday. The business has a fifty day simple moving average of $19.08 and a 200 day simple moving average of $16.89. Avalo Therapeutics, Inc. has a 1 year low of $8.73 and a 1 year high of $24.27. The company has a market capitalization of $1.04 billion, a PE ratio of -4.43 and a beta of 0.78.

Avalo Therapeutics (NASDAQ:AVTX) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.25). Equities analysts anticipate that Avalo Therapeutics, Inc. will post -2.59 earnings per share for the current fiscal year.

Avalo Therapeutics Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.